Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II

• Chuqi Lei,
• Xiangyi Kong,
• Xiangyi Kong,
• Ryan J. Sullivan,
• Caisheng Wu,
• Caisheng Wu,
• Dawei Wang,
• Lin Zhang,
• Lin Zhang,
• Lin Zhang

Affiliations

Chuqi Lei

Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cance, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Xiangyi Kong

Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cance, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Xiangyi Kong

Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

Ryan J. Sullivan

Center for Melanoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA, United States

Caisheng Wu

Laboratory Animal Center, Xiamen University, Xiamen, China

Caisheng Wu

School of Pharmaceutical Sciences, Xiamen University, Xiamen, China

Dawei Wang

Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Lin Zhang

Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, China

Lin Zhang

Suzhou Industrial Park Monash Research Institute of Science and Technology, Suzhou, China

Lin Zhang

School of Population Medicine and Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China